NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Reckitt's India Business Reports Double-Digit Growth in Q1 2026

British fast-moving consumer goods (FMCG) major Reckitt's India business has reported a double-digit growth in the first quarter of 2026, driven by strong growth of its key brands, including Dettol, Durex, and expansion in the coverage area.

Reckitt's India business was led by two of its key brands, Dettol in the Germ Protection segment and Durex in Intimate Wellness, which both reported double-digit growth in the quarter. At the group level, Reckitt's net revenue stood at 3.24 billion pounds, with a like-for-like (LFL) growth of 0.6 per cent in Q1 2026. The company's volume growth was 2 per cent.

The quarter was impacted by low seasonal incidence, weak categories in Europe, and geopolitical disruption, according to Reckitt's earnings statement. However, the company's 'Core Reckitt', which houses its 11 high-growth Powerbrands, reported a net revenue growth of 1.3 per cent in the first quarter, driven by emerging markets.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Key Growth Figures

RegionQ1 2026 LFL GrowthQ1 2026 Volume GrowthQ1 2026 Price/Mix Improvement
Emerging Markets7.6%0.5%7.1%
Core Reckitt1.3%N/AN/A
IndiaDouble-Digit GrowthN/AN/A

The growth in Core Reckitt was led by emerging markets, with double-digit growth in China and India, and mid-single-digit growth in non-seasonal brands in North America. Reckitt's net revenue from emerging markets, which includes high-growth developing regions such as India, China, LATAM, Vietnam, and Indonesia, grew 7.6 per cent on a LFL basis in Q1 2026 to 1.09 billion pounds, with 0.5 per cent volume growth and 7.1 per cent price/mix improvement.

In India, Reckitt's business delivered double-digit growth in Q1 2026, led by strong growth in Germ Protection (Dettol), Intimate Wellness (Durex), and Household Care (Finish) categories. The company's ongoing sales transformation drove expanded coverage, enhancing execution.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

Emerging markets also contributed 42 per cent of Core Reckitt's Q1 2026 net revenues, according to the company's earnings statement. Core Reckitt includes 11 high-growth and high-margin brands, including Dettol, Lysol, Durex, and Harpic, operating in hygiene, health, and nutrition categories.

Reckitt has maintained its LFL net revenue guidance and expects continued strong growth across China and India, among others. The company's Chief Executive Officer, Kris Licht, stated that the growth will be driven by sequential growth from market-leading Powerbrands, as the season resets and the company continues to launch superior innovations.

The company's outlook for the future is positive, with expectations of continued strong growth across key markets.

Investor Takeaway

Investors should focus on emerging markets for growth opportunities.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.